Back to Journals » Patient Preference and Adherence » Volume 9

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

Authors Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, Suenaga M, Mizunuma N, Oniyama S, Machida Y, Yamaguchi T, Hama T

Received 5 January 2015

Accepted for publication 24 February 2015

Published 9 April 2015 Volume 2015:9 Pages 561—567

DOI https://doi.org/10.2147/PPA.S80327

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen


Kazuyoshi Kawakami,1 Eri Nakamoto,1 Takashi Yokokawa,1 Kazuo Sugita,1 Yutarou Mae,1 Akane Hagino,1 Mitsukuni Suenaga,2 Nobuyuki Mizunuma,2 Sayaka Oniyama,3 Yoshiaki Machida,3 Toshiharu Yamaguchi,2 Toshihiro Hama1

1Department of Pharmacy, 2Gastroenterology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3Section for Practical Education, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

Background: Capecitabine plus oxaliplatin (XELOX) has been established as a first-line treatment for metastatic colorectal cancer. Adherence is particularly important with capecitabine to maintain appropriate curative effect. In this study, we monitored the adherence to capecitabine on XELOX treatment and investigated which factors might decrease compliance.
Methods: The study included 242 consecutive patients who received XELOX treatment for metastatic colorectal cancer between October 2009 and March 2012. Adherence to capecitabine was checked by pharmacists with a patient-reported treatment diary at a pharmaceutical outpatient clinic. Adherence rate was defined as the number of times that a patient took capecitabine in a 14-day cycle/28 prescribed doses. We retrospectively surveyed median relative dose intensities of capecitabine and the factors deteriorating adherence across eight cycles from electronic patient records and examined differences in compliance rates according to age.
Results: The study included 144 male and 98 female patients. The overadherence rate was 1.5% (n=23). The median adherence rate was 93.5% (n=242) in the first cycle of XELOX treatment, which gradually rose to 96.1% (n=148) in the eighth cycle. The median relative dose intensity of capecitabine was 79.2%. The main factors contributing to decreased adherence to capecitabine were diarrhea (22.5%, 352 instances) and nausea/vomiting (13.8%, 215 instances). The rate of missed dose was 12.1%. Analysis of adherence issues in relation to patient age showed a trend toward worse adherence to capecitabine therapy in the group of patients aged ≥80 years (hazard ratio =3.83; 95% confidence interval 2.48–5.91, P<0.001 versus 70–80 years group and versus <70 years group, chi-square test).
Conclusion: Patient-reported adherence to capecitabine on XELOX treatment in clinical practice is high but adversely affected by side effects. Patients aged 80 years or more exhibit a significant decrease in compliance compared with younger patients.

Keywords: pharmaceutical outpatient clinic, oral anticancer drugs
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]